Progen Industries to Conduct Phase I Trial of PI-88 and Docetaxel

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

BRISBANE, Australia-Progen Industries is conducting a phase I trial combining its cancer drug PI-88 with docetaxel (Taxotere) in patients with advanced malignancies. The trial is taking place at the University of Colorado Cancer Center,

BRISBANE, Australia—Progen Industries is conducting a phase I trial combining its cancer drug PI-88 with docetaxel (Taxotere) in patients with advanced malignancies. The trial is taking place at the University of Colorado Cancer Center, Denver, with Scott Holden, MD, as principal investigator, Progen said in a news release.

PI-88 is a semisynthetic sulfated oligosaccharide that has several modes of action. In animal models it has been shown to prevent angiogenesis by inhibiting fibroblast growth factor, and to block metastasis by inhibiting the enzyme heparinase, which allows cancer cells to escape blood vessels. It also stimulates sustained release of TFPI (tissue factor pathway inhibitor), a natural inhibitor of angiogenesis, from cells lining the blood vessel wall.

Related Videos
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Related Content